Eli Lilly Oncology Drug Olomorasib Receives FDA Orphan Drug Designation
Eli Lilly's experimental cancer treatment, olomorasib, has received orphan drug designation from the Food and Drug Administration, marking a regulatory win for the company's oncology pipeline.
By Mackenzie TatananniAnother day, another chance for Eli Lilly to prove it is more than just a leader in weight-loss drugs. The Food and Drug Administration on Monday granted olomorasib orphan dr…